Johnson & Johnson in deal with Australia University for spider venom pain research
UniQuest, Australian University of Queensland’s (UQ) main research commercialization company, says that researchers at the Institute for Molecular Bioscience (IMB) have entered into an agreement for a focused funding grant and collaborative research project with US health care giant Johnson & Johnson (NYSE: JNJ) and certain of its Janssen affiliates, to develop components of spider venom that may be effective as a treatment for pain.
The grant funding will support a 12-month project to characterise novel spider venom peptides that were discovered in a proprietary IMB assay to inhibit a human ion channel, critical for sensing pain. The long-term goal is to develop these peptides for the therapeutic treatment of chronic pain. The project team includes Professors Glenn King, Richard Lewis, Paul Alewood and their research teams. Financial terms of the deal were not disclosed.
Chronic pain a $560 billion annual cost in USA
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze